| George Ezeji, MD | |
|
205 Grandview Ave Ste 301, Camp Hill, PA 17011-1704 | |
| (717) 695-0394 | |
| (717) 695-0398 |
| Full Name | George Ezeji |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 23 Years |
| Location | 205 Grandview Ave Ste 301, Camp Hill, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073908695 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | MD471029 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Pinnacle Health Hospitals | Harrisburg, PA | Hospital |
| Holy Spirit Hospital | Camp hill, PA | Hospital |
| Carlisle Regional Medical Center | Carlisle, PA | Hospital |
| Chambersburg Hospital | Chambersburg, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pinnacle Health Medical Services | 7618960493 | 942 |
| Associates In Kidney Diseases Hypertension And Intensive Care Medicine | 8921162769 | 3 |
News Archive
Chindex International, Inc. (Nasdaq: CHDX), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced results for its first quarter of fiscal 2010, ended June 30, 2009.
Last year, Charles O. Elson, M.D., demonstrated a potential preventive treatment for Crohn's disease, a form of inflammatory bowel disease. He used a mouse model that included immune-reactive T cells from patients with Crohn's disease in a flagellin peptide-specific immunotherapy.
One of the unfortunate side effects of bone marrow and stem cell transplantation is that the newly implanted cells often stage an internal attack against the patient they're intended to help.
A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease.
› Verified 9 days ago
| Entity Name | Franklin County Medical Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083640254 PECOS PAC ID: 4284527250 Enrollment ID: O20040204000256 |
News Archive
Chindex International, Inc. (Nasdaq: CHDX), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced results for its first quarter of fiscal 2010, ended June 30, 2009.
Last year, Charles O. Elson, M.D., demonstrated a potential preventive treatment for Crohn's disease, a form of inflammatory bowel disease. He used a mouse model that included immune-reactive T cells from patients with Crohn's disease in a flagellin peptide-specific immunotherapy.
One of the unfortunate side effects of bone marrow and stem cell transplantation is that the newly implanted cells often stage an internal attack against the patient they're intended to help.
A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease.
› Verified 9 days ago
| Entity Name | Pinnacle Health Medical Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932143427 PECOS PAC ID: 7618960493 Enrollment ID: O20040407000180 |
News Archive
Chindex International, Inc. (Nasdaq: CHDX), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced results for its first quarter of fiscal 2010, ended June 30, 2009.
Last year, Charles O. Elson, M.D., demonstrated a potential preventive treatment for Crohn's disease, a form of inflammatory bowel disease. He used a mouse model that included immune-reactive T cells from patients with Crohn's disease in a flagellin peptide-specific immunotherapy.
One of the unfortunate side effects of bone marrow and stem cell transplantation is that the newly implanted cells often stage an internal attack against the patient they're intended to help.
A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease.
› Verified 9 days ago
| Entity Name | Associates In Kidney Diseases Hypertension And Intensive Care Medicine |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275784498 PECOS PAC ID: 8921162769 Enrollment ID: O20090123000036 |
News Archive
Chindex International, Inc. (Nasdaq: CHDX), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced results for its first quarter of fiscal 2010, ended June 30, 2009.
Last year, Charles O. Elson, M.D., demonstrated a potential preventive treatment for Crohn's disease, a form of inflammatory bowel disease. He used a mouse model that included immune-reactive T cells from patients with Crohn's disease in a flagellin peptide-specific immunotherapy.
One of the unfortunate side effects of bone marrow and stem cell transplantation is that the newly implanted cells often stage an internal attack against the patient they're intended to help.
A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| George Ezeji, MD Po Box 3877, Joliet, IL 60434-3877 Ph: (815) 714-7171 | George Ezeji, MD 205 Grandview Ave Ste 301, Camp Hill, PA 17011-1704 Ph: (717) 695-0394 |
News Archive
Chindex International, Inc. (Nasdaq: CHDX), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced results for its first quarter of fiscal 2010, ended June 30, 2009.
Last year, Charles O. Elson, M.D., demonstrated a potential preventive treatment for Crohn's disease, a form of inflammatory bowel disease. He used a mouse model that included immune-reactive T cells from patients with Crohn's disease in a flagellin peptide-specific immunotherapy.
One of the unfortunate side effects of bone marrow and stem cell transplantation is that the newly implanted cells often stage an internal attack against the patient they're intended to help.
A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease.
› Verified 9 days ago
Dr. Krishna Reddy Dondeti, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 503 N 21st St, Camp Hill, PA 17011 Phone: 717-972-4448 Fax: 717-972-7366 | |
Mohammad Shahriar Hussain Rumi, MBBS Nephrology Medicare: Accepting Medicare Assignments Practice Location: 503 N 21st St, Camp Hill, PA 17011 Phone: 717-972-4448 Fax: 717-972-7366 | |
Dr. Amit Kumar Misra, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 503 N 21st St, Camp Hill, PA 17011 Phone: 717-972-4448 Fax: 717-972-7366 | |
Maurice J. Lewis, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 890 Poplar Church Rd, Suite 508, Camp Hill, PA 17011 Phone: 717-761-3875 Fax: 717-761-7893 | |
Dr. Robert Denes Kusztos, MD Nephrology Medicare: Medicare Enrolled Practice Location: 4400 Carlisle Pike, Camp Hill, PA 17011 Phone: 717-975-9800 Fax: 717-975-5509 | |
Dr. Chandrasekhar Reddy Dinasarapu, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 503 N. 21st Street, Camp Hill, PA 17011 Phone: 717-972-4448 Fax: 717-972-7366 |